SwanBio Therapeutics Funding: $133M Raised, Series B (2022)
SwanBio Therapeutics is based in Bala Cynwyd. It has raised $133M in total funding. Latest round: Series B.
SwanBio Therapeutics funding overview
SwanBio Therapeutics is based in Bala Cynwyd. SwanBio Therapeutics has raised $133M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B announced in May 2022. The round record for SwanBio Therapeutics runs through 2022; nothing later has been disclosed. Investors on record include Syncona Limited, Mass General Brigham Ventures, Partners Innovation Fund. 3 distinct backers are named across the disclosed rounds.
SwanBio Therapeutics at a glance
Total raised
$133M
Latest round
Series B
Latest round date
May 2022
Headquarters
Bala Cynwyd
Notable investors
Syncona Limited, Mass General Brigham Ventures, Partners Innovation Fund
Frequently asked about SwanBio Therapeutics funding
How much has SwanBio Therapeutics raised?
SwanBio Therapeutics has raised $133M in total disclosed funding across the rounds on record.
Who has invested in SwanBio Therapeutics?
Syncona Limited, Mass General Brigham Ventures, Partners Innovation Fund are named among the investors backing SwanBio Therapeutics.
What was the latest SwanBio Therapeutics funding round?
The most recent disclosed round is a Series B, announced in May 2022.
Where is SwanBio Therapeutics based?
SwanBio Therapeutics is based in Bala Cynwyd.
When did SwanBio Therapeutics last raise?
The last disclosed SwanBio Therapeutics round closed in May 2022 at Series B.
SwanBio Therapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Bala Cynwyd below to benchmark round size and investor mix.
